Post hoc analysis of a phase 3 trial demonstrates durable disease control with guselkumab in psoriatic arthritis, suggesting efficacy across subgroups.
Evaluate patterns of stringent disease control with 2 years of guselkumab across key disease-identified domains and patient-reported outcomes (PROs) in subgroups of patients with psoriatic arthritis (PsA) defined by baseline characteristics.
No takes yet. Share an insight, caveat, or question.
Ritchlin et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: